Here we performed clinical, in vitro and in vivo analyses to assess crosstalk between the BRD/c-Myc axis and the integrin/FAK-dependent pathway in breast cancer and their potential as targets for a synthetic lethal-type therapy. The gene discussed is MYC; the disease is breast cancer.